Urinary bladder cancer

Clinical Obstetrics and Gynecology

Volumn 45, Issue 3, 2002, Pages 844-854

  Wai, Clifford Y ^a   Miller, David Scott ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CAFFEINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; IMMUNOMODULATING AGENT; METHOTREXATE; MITOMYCIN C; SWEETENING AGENT; THIOTEPA; VINBLASTINE;

AGE DISTRIBUTION; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CYSTECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; OCCUPATIONAL EXPOSURE; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RACE DIFFERENCE; REVIEW; SEX RATIO; SMOKING; SYMPTOMATOLOGY; VIRUS INFECTION; WART VIRUS;

ALGORITHMS; ANIMALS; FEMALE; HEMATURIA; HUMANS; NEOPLASM STAGING; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0036408398     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200209000-00031     Document Type: Review

References (28)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun MT. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Sternberg CN. A critical review of the management of bladder cancer. Crit Rev Oncol Hematol. 1999;31:193-207.
3. Droller MJ, Bladder cancer: State-of-the-art care. CA Cancer J Clin. 1998;48:269-284.
4. Van der Poel HG, Mungan NA, Witjes JA. Bladder cancer in women. Int Urogynecol J. 1999;10:207-212.
5. Benson RC Jr, Tomera KM, Kelalis PP. Transitional cell carcinomas of the bladder in children and adolescents. J Urol. 1983b;130:54.
6. Messing EM, Catalona W. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology, 7th Ed. Philadelphia: WB Saunders, 1998:2329-2410.
7. Cohen SM, Johansson SL. Epidemiology and etiology of bladder cancer. Urol Clin North Am. 1992;19:421-428.
8. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 1992;6:1-30.
9. Kantor AF, Hartge P, Hoover RN, Fraumeni JF. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res. 1988;48:3853-3855.
10. Baniel J. Bladder cancer in women. Int Urogynecol J. 1999;10:399-404.
11. Cole P. Coffee drinking and cancer of the lower urinary tract. Lancet. 1971;1:1335-1337.
12. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organisation/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. Am J Surg Pathol. 1998;22(12):1435-1448.
13. Lopez-Beltran A, Munoz A. Transitional cell carcinoma of the bladder: Low incidence of human papillomavirus DNA detected by the polymerase chain reaction and in situ hybridization. Histopathology. 1995;26:565-569.
14. Boucher NR, Anderson JB. Human papillomavirus and bladder cancer. Int Urogynecol J. 1997;8:354-357.
15. Cespedes RD, Peretsman SJ, Blatt SP. The significance of hematuria in patients infected with the human immunodeficiency virus. J Urol. 1995;154:1455-1456.
16. Mvula M, Iwasaka T, Iguchi A, et al. Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? J Urol. 1996;155:471-474.
17. International Union Against Cancer (UICC). In: Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 5th ed. New York: Wiley-Liss, 1997.
18. Lapham RL, Ro JY, Staerkel GA, Ayala AG. Pathology of transitional cell carcinoma of the bladder and its clinical implications. Semin Surg Oncol 1997;13:307-318.
19. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: Progression and recurrence. J Urol, 1983;130(6):1083-1086.
20. Whitmore WF. Bladder cancer: An overview. CA Cancer J Clin. 1988;38:213-223.
21. Ozen H. Transitional cell carcinoma of the bladder. Curr Opin Oncol. 1994;6:313-317.
22. Mommsen S, Asgaard J, Sell A. Presenting symptoms, treatment delay and survival in bladder cancer. Scand J Urol Nephrol. 1983;17:163-166.
23. Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin North Am. 1992;19:455-465.
24. Hiatt RA, Ordonez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev. 1994;3:439.
25. Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: The American Urologic Association Best Practice Policy - Part II: Patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology. 2001;57:604-611.
26. Rife CC, Farrow GM, Utz DC. Urine cytology of transitional cell neoplasms. Urol Clin North Am. 1979;6(3):599-612.
27. Lamm DL. Bladder cancer: Twenty years of progress and the challenges that remain. CA Cancer J Clin. 1998;48:263-268.
28. Gupta NP, Dorairajan LN. Transurethral resection of a bladder tumor in pregnancy: A report of 2 cases. Int Urogynecol J. 1997;8:230-232.